118th Congress Health
H.R. 5547: Maintaining Investments in New Innovation Act
Introduced
- Introduced (completed)
- Passed House (not reached)
- Passed Senate (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Cosponsors
- Donald Davis D-NCOriginal
- John Joyce R-PAOriginal
- Scott Peters D-CA
- Dan Crenshaw R-TX
- Larry Bucshon R-IN
- Richard Hudson R-NC
- A. Ferguson R-GA
- Rick Allen R-GA
- Diana Harshbarger R-TN
- Daniel Meuser R-PA
- Blake Moore R-UT
- Adrian Smith R-NE
- Mariannette Miller-Meeks R-IA
- Nicole Malliotakis R-NY
- Vern Buchanan R-FL
- Mike Carey R-OH
- Beth Van Duyne R-TX
- Sheila Cherfilus-McCormick D-FL
- Mike Kelly R-PA
- Lloyd Smucker R-PA
- Michael Burgess R-TX
- Neal Dunn R-FL
- Josh Gottheimer D-NJ
- Claudia Tenney R-NY
- Kevin Hern R-OK
- August Pfluger R-TX
- Ken Calvert R-CA
- Joseph Morelle D-NY
Who scored on this bill
- 1Wiley Nickel SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone3 events+12
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
History
- Introduced in the House by Wiley Nickel.
Show the full action history (4 actions)
- Referred to the Subcommittee on Health.
- Referred to the Subcommittee on Health.
- Introduced in House
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.